|Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.|
|PMID: 23279219 Owner: NLM Status: MEDLINE|
|BACKGROUND: Rituximab has been documented in the treatment of acute (≤ 3 days from admission), relapsed/refractory thrombotic thrombocytopenic purpura (TTP) and given as prophylaxis in selected cases to prevent acute relapse. The precise timing of rituximab in acute TTP has not been determined.
OBJECTIVE: To perform a retrospective analysis of rituximab use in a large TTP referral center over an 8-year period.
PATIENTS/METHODS: We assessed response to treatment and outcome for all patients treated with rituximab, including 91 patients presenting with 104 episodes of acute TTP and 15 patients given rituximab as prophylaxis to prevent relapse. In the acute TTP group we assessed the benefit of giving early (≤ 3 days from admission) vs. later (> 3 days) rituximab.
RESULTS: In acute de novo TTP, previously untreated with rituximab, rituximab was given ≤ 3 days from admission to 54 patients and > 3 days from admission to 32 patients. Earlier administration (≤ 3 days) was associated with faster attainment of remission (12 vs. 20 days, P < 0.001), fewer plasma exchanges (16 vs. 24, P = 0.03) and shorter hospital stay (16 vs. 23 days, P = 0.01). Eighty-two patients (95%) achieved complete remission within 14 days (4-52 days); four patients died acutely. Eleven out of 82 (13.4%) relapsed at a median of 24 months (4-49 months). Rituximab prophylaxis was associated with normalization of ADAMTS13 levels within 3 months in all but one case, with only one acute relapse at follow-up.
CONCLUSIONS: Although limited by being retrospective and non-randomized, this study demonstrates the potential benefit of early administration of rituximab in acute TTP, and prophylactic use to prevent acute relapse.
|J-P Westwood; H Webster; S McGuckin; V McDonald; S J Machin; M Scully|
Related Documents :
|7807449 - Audit of major gastrointestinal surgery in patients aged 80 years or over.
7588929 - The value of dipyridamole echocardiography in risk stratification before vascular surge...
24775519 - The magnitude of the variation in glycemia: a new parameter for risk assessment in acut...
24321239 - Initial results of using a novel irrigated multielectrode mapping and ablation catheter...
20814469 - Electrocardiogram interpretation skills in pediatric residents.
9237599 - Perioperative risk factors affecting hospital stay and hospital costs in open heart sur...
19083589 - Comparison of results of wire subcision performed alone, with fills, and/or with adjace...
22343689 - Comparative efficacy of different doses of fibrin sealant to reduce bleeding after tota...
22158109 - Lipid metabolism disturbances and ampk activation in prolonged propofol-sedated rabbits...
|Type: Journal Article; Research Support, Non-U.S. Gov't|
|Title: Journal of thrombosis and haemostasis : JTH Volume: 11 ISSN: 1538-7836 ISO Abbreviation: J. Thromb. Haemost. Publication Date: 2013 Mar|
|Created Date: 2013-03-15 Completed Date: 2013-08-30 Revised Date: 2014-02-20|
Medline Journal Info:
|Nlm Unique ID: 101170508 Medline TA: J Thromb Haemost Country: England|
|Languages: eng Pagination: 481-90 Citation Subset: IM|
|© 2012 International Society on Thrombosis and Haemostasis.|
|APA/MLA Format Download EndNote Download BibTex|
Antibodies, Monoclonal, Murine-Derived / administration & dosage*, adverse effects
Biological Markers / blood
Drug Administration Schedule
Immunologic Factors / administration & dosage*, adverse effects
Purpura, Thrombotic Thrombocytopenic / blood, diagnosis, drug therapy*, mortality
Tertiary Care Centers
|G0800671//Medical Research Council; //Medical Research Council|
|0/Antibodies, Monoclonal, Murine-Derived; 0/Biological Markers; 0/Immunologic Factors; 0/rituximab; EC 3.4.24.-/ADAM Proteins; EC 3.4.24.-/ADAMTS13 protein, human|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic...
Next Document: The role of galectin-3 in phagocytosis of Candida albicans and Candida parapsilosis by human neutrop...